148 related articles for article (PubMed ID: 22221673)
1. N-3 long-chain polyunsaturated fatty acids inhibit smooth muscle cell migration by modulating urokinase plasminogen activator receptor through MEK/ERK-dependent and -independent mechanisms.
Whyte C; Thies F; Peyrol L; Balcerzak D
J Nutr Biochem; 2012 Nov; 23(11):1378-83. PubMed ID: 22221673
[TBL] [Abstract][Full Text] [Related]
2. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-receptor-mediated phenotypic changes in vascular smooth muscle cells require the involvement of membrane rafts.
Kiyan J; Smith G; Haller H; Dumler I
Biochem J; 2009 Oct; 423(3):343-51. PubMed ID: 19691446
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
5. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
7. Urokinase receptor associates with myocardin to control vascular smooth muscle cells phenotype in vascular disease.
Kiyan Y; Limbourg A; Kiyan R; Tkachuk S; Limbourg FP; Ovsianikov A; Chichkov BN; Haller H; Dumler I
Arterioscler Thromb Vasc Biol; 2012 Jan; 32(1):110-22. PubMed ID: 22075245
[TBL] [Abstract][Full Text] [Related]
8. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
9. The tyrosine phosphatase SHP-2 controls urokinase-dependent signaling and functions in human vascular smooth muscle cells.
Kiyan J; Haller H; Dumler I
Exp Cell Res; 2009 Apr; 315(6):1029-39. PubMed ID: 19133257
[TBL] [Abstract][Full Text] [Related]
10. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
11. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.
Zhang G; Cai X; López-Guisa JM; Collins SJ; Eddy AA
J Am Soc Nephrol; 2004 Aug; 15(8):2090-102. PubMed ID: 15284295
[TBL] [Abstract][Full Text] [Related]
12. Relationship between urokinase plasminogen activator receptor (uPAR) and the invasion of human prenatal hair follicle.
Gao Q; Fu G; Huang G; Lian X; Yu J; Yang T
Arch Dermatol Res; 2010 Aug; 302(6):409-18. PubMed ID: 20012874
[TBL] [Abstract][Full Text] [Related]
13. Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migration.
Pliyev BK; Antonova OA; Menshikov M
Mol Immunol; 2011 May; 48(9-10):1168-77. PubMed ID: 21470685
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells.
Gupta R; Chetty C; Bhoopathi P; Lakka S; Mohanam S; Rao JS; Dinh DE
Int J Oncol; 2011 Mar; 38(3):733-44. PubMed ID: 21181094
[TBL] [Abstract][Full Text] [Related]
15. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
16. Aggregated low-density lipoprotein induce impairment of the cytoskeleton dynamics through urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor in human vascular smooth muscle cell.
Lugano R; Peña E; Badimon L; Padró T
J Thromb Haemost; 2012 Oct; 10(10):2158-67. PubMed ID: 22906080
[TBL] [Abstract][Full Text] [Related]
17. MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.
Bessard A; Frémin C; Ezan F; Coutant A; Baffet G
J Cell Physiol; 2007 Aug; 212(2):526-36. PubMed ID: 17427199
[TBL] [Abstract][Full Text] [Related]
18. LR11, an LDL receptor gene family member, is a novel regulator of smooth muscle cell migration.
Zhu Y; Bujo H; Yamazaki H; Ohwaki K; Jiang M; Hirayama S; Kanaki T; Shibasaki M; Takahashi K; Schneider WJ; Saito Y
Circ Res; 2004 Apr; 94(6):752-8. PubMed ID: 14764453
[TBL] [Abstract][Full Text] [Related]
19. Ablation of MEK kinase 1 suppresses intimal hyperplasia by impairing smooth muscle cell migration and urokinase plasminogen activator expression in a mouse blood-flow cessation model.
Li Y; Minamino T; Tsukamoto O; Yujiri T; Shintani Y; Okada K; Nagamachi Y; Fujita M; Hirata A; Sanada S; Asanuma H; Takashima S; Hori M; Johnson GL; Kitakaze M
Circulation; 2005 Apr; 111(13):1672-8. PubMed ID: 15795331
[TBL] [Abstract][Full Text] [Related]
20. The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator.
Maupas-Schwalm F; Augé N; Robinet C; Cambus JP; Parsons SJ; Salvayre R; Nègre-Salvayre A
FASEB J; 2004 Sep; 18(12):1398-400. PubMed ID: 15231724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
